BNTC - NASDAQ
Benitec Biopharma Inc.
$11.05
+4.4%Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
At a Glance
Live Snapshotbntc
Cash and Short Term Investments
Last Annual Value
97.74M
3-Year CAGR
189%
5-Year CAGR
58%
10-Year CAGR
19%
Benitec Biopharma Inc. Competitors Analysis of Cash and Short Term Investments
| Company | Cash and Short Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Benitec Biopharma Inc. NASDAQ:BNTC | 97.74M | 240.5% | 37.7% | 21.8% | |
 I-Mab NASDAQ:IMAB | 173.40M | -57.7% | -23.7% | N/A | |
 Aura Biosciences, Inc. NASDAQ:AURA | 144.24M | -13.9% | -0.7% | N/A | |
 DiaMedica Therapeutics Inc. NASDAQ:DMAC | 59.89M | 4.2% | 5.8% | 42.5% | |
 Design Therapeutics, Inc. NASDAQ:DSGN | 219.84M | -7.9% | -10.6% | N/A | |
 Humacyte, Inc. NASDAQ:HUMA | 50.50M | -14.4% | -25.9% | N/A | |
 Korro Bio, Inc. NASDAQ:KRRO | 75.16M | -23.2% | -10.5% | N/A | |
 RAPT Therapeutics, Inc. NASDAQ:RAPT | 231.06M | 13.3% | 4.0% | N/A | |
 Lineage Cell Therapeutics, Inc. AMEX:LCTX | 55.78M | 16.3% | -0.9% | 9.4% | |
 PureTech Health plc NASDAQ:PRTC | 278.89M | -5.2% | -9.7% | -0.1% | |
 Galectin Therapeutics Inc. NASDAQ:GALT | 17.72M | -11.6% | -14.9% | 1.4% |
Benitec Biopharma Inc. Fair Value Envelope
Related Guides
Continue your BNTC research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.